Evidence map›Paper›PMID 27852695›Full record

Trial reportHeart (British Cardiac Society)2017

Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis.

Francis O'Neill, Marietta Charakida, Eric Topham, Eve McLoughlin, Neha Patel, Emma Sutill, Christopher W M Kay, Francesco D'Aiuto, Ulf Landmesser, Peter C Taylor and 1 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Heart (British Cardiac Society), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Advances in Atherosclerosis Theranostics Harnessing Iron Oxide-Based Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 4 countries.

Francis O'NeillVascular Physiology Unit, Institute of Cardiovascular Science, University College London, London, UK.
Marietta CharakidaVascular Physiology Unit, Institute of Cardiovascular Science, University College London, London, UK.
Eric TophamInstitute of Structural & Molecular Biology and London Centre for Nanotechnology, University College London, London, UK.
Eve McLoughlinVascular Physiology Unit, Institute of Cardiovascular Science, University College London, London, UK.
Neha PatelVascular Physiology Unit, Institute of Cardiovascular Science, University College London, London, UK.
Emma SutillVascular Physiology Unit, Institute of Cardiovascular Science, University College London, London, UK.
Christopher W M KayInstitute of Structural & Molecular Biology and London Centre for Nanotechnology, University College London, London, UK.
Francesco D'AiutoPeriodontology Unit, Department of Clinical Research, University College London Eastman Dental Institute, London, UK.
Ulf LandmesserDepartment of Cardiology, Charite Universitätsmedizin Berlin, Berlin, Germany.
Peter C TaylorKennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
John DeanfieldVascular Physiology Unit, Institute of Cardiovascular Science, University College London, London, UK.
University College London · GBCharité - Universitätsmedizin Berlin · DEInstitute of Structural and Molecular Biology · GBLondon Centre for Nanotechnology · GBUniversity of Oxford · GB

Funding

Medical Research Council MR/K006584/1
6 · The paper itself

Abstract

objectivePatients with rheumatoid arthritis (RA) are at increased cardiovascular risk. Recent studies suggest that high-density lipoprotein (HDL) may lose its protective vascular phenotype in inflammatory conditions. However, the effects of common anti-inflammatory treatments on HDL function are not yet known.

methodsWe compared the function of HDL in 18 patients with RA and 18 matched healthy controls. Subsequently, patients were randomised to (methotrexate+infliximab (M+I) (5 mg/kg)) or methotrexate+placebo (M+P) infusions for 54 weeks. At week 54 and thereafter, all patients received infliximab therapy until completion of the trial (110 weeks), enabling assessment of the impact of 1 year of infliximab therapy in all patients. HDL functional properties were assessed at baseline, 54 weeks and 110 weeks by measuring the impact on endothelial nitric oxide (NO) bioavailability and superoxide production (SO), paraoxonase activity (PON-1) and cholesterol efflux.

resultsAll HDL vascular assays were impaired in patients compared with controls. After 54 weeks, NO in response to HDL was significantly greater in patients who received M+I compared with those who received M+P. Endothelial SO in response to HDL was reduced in both groups, but PON-1 and cholesterol efflux remained unchanged. All vascular measures improved compared with baseline after ≥1 infliximab therapy in the analysis at 110 weeks. No significant trend was noted for cholesterol efflux.

conclusionsHDL function can be improved with anti-inflammatory treatment in patients with RA. The M+I combination was superior to the M+P alone, suggesting that the tumour necrosis factor-α pathway may have a role in HDL vascular properties.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidBiomarkersCardiovascular DiseasesDose-Response Relationship, DrugDrug Therapy, CombinationFemaleFollow-Up StudiesHumansInfliximabInfusions, IntravenousLipoproteins, HDLMaleMethotrexateMiddle AgedRetrospective StudiesAntirheumatic AgentsBiomarkersInfliximabLipoproteins, HDLMethotrexate

Identifiers

PMID27852695
PMCPMC5529963
OpenAlexW2555879348

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.